$KRBP
Kiromic Biopharma, Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023019028 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.517M $2.875M
YoY Change -29.91% -37.67%
% of Gross Profit
Research & Development $2.800M $2.677M
YoY Change -15.9% -29.25%
% of Gross Profit
Depreciation & Amortization $555.6K $560.1K
YoY Change 0.13% 4.38%
% of Gross Profit
Operating Expenses $5.318M $5.552M
YoY Change -23.17% -33.88%
Operating Profit -$5.552M
YoY Change -33.88%
Interest Expense -$632.9K -$433.8K
YoY Change 296.55% -31085.71%
% of Operating Profit
Other Income/Expense, Net $1.260M $1.792M
YoY Change -151.75%
Pretax Income -$4.691M -$4.194M
YoY Change -33.63% -64.64%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.660M -$4.194M
YoY Change -20.89% -64.64%
Net Earnings / Revenue
Basic Earnings Per Share -$1.52
Diluted Earnings Per Share -$4.46 -$1.52
COMMON SHARES
Basic Shares Outstanding 1.258M 1.176M
Diluted Shares Outstanding 1.190M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.204M $4.380M
YoY Change 396.59% 912.13%
Cash & Equivalents $3.204M $4.380M
Short-Term Investments
Other Short-Term Assets $1.226M $1.558M
YoY Change 17.47% -8.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.430M $5.938M
YoY Change 162.3% 177.7%
LONG-TERM ASSETS
Property, Plant & Equipment $6.175M $6.582M
YoY Change -24.11% -24.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.40K $21.40K
YoY Change -12.3% -31.19%
Total Long-Term Assets $7.739M $8.296M
YoY Change -24.71% -23.76%
TOTAL ASSETS
Total Short-Term Assets $4.430M $5.938M
Total Long-Term Assets $7.739M $8.296M
Total Assets $12.17M $14.23M
YoY Change 1.68% 9.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.136M $4.247M
YoY Change -70.77% -34.6%
Accrued Expenses $4.242M $3.743M
YoY Change 163.81% -18.88%
Deferred Revenue
YoY Change
Short-Term Debt $14.00M $57.50K
YoY Change 2412.56%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.38M $17.65M
YoY Change 53.41% 58.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $911.5K $1.073M
YoY Change -41.0% -34.02%
Total Long-Term Liabilities $911.5K $1.073M
YoY Change -79.56% -34.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.38M $17.65M
Total Long-Term Liabilities $911.5K $1.073M
Total Liabilities $21.29M $18.72M
YoY Change 20.0% 47.0%
SHAREHOLDERS EQUITY
Retained Earnings -$122.9M -$118.2M
YoY Change 20.55% 24.58%
Common Stock $1.258K $1.176K
YoY Change 94.14% -87.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.121M -$4.487M
YoY Change
Total Liabilities & Shareholders Equity $12.17M $14.23M
YoY Change 1.68% 9.33%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.660M -$4.194M
YoY Change -20.89% -64.64%
Depreciation, Depletion And Amortization $555.6K $560.1K
YoY Change 0.13% 4.38%
Cash From Operating Activities -$5.407M -$5.228M
YoY Change 31.8% -14.23%
INVESTING ACTIVITIES
Capital Expenditures $109.1K $97.50K
YoY Change 90.73% -26.36%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$109.1K -$97.50K
YoY Change 158.53% -173.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.341M 7.000M
YoY Change -0.37% -6192.08%
NET CHANGE
Cash From Operating Activities -5.407M -5.228M
Cash From Investing Activities -109.1K -97.50K
Cash From Financing Activities 4.341M 7.000M
Net Change In Cash -1.176M 1.674M
YoY Change -653.18% -127.55%
FREE CASH FLOW
Cash From Operating Activities -$5.407M -$5.228M
Capital Expenditures $109.1K $97.50K
Free Cash Flow -$5.516M -$5.326M
YoY Change 32.62% -14.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001792581
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Security Exchange Name
SecurityExchangeName
NONE
CY2022Q1 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2022Q2 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2021Q4 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2021Q3 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
648384
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1176260
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1176260
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
648384
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
14000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39619
dei Entity Registrant Name
EntityRegistrantName
Kiromic BioPharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4762913
dei Entity Address Address Line1
EntityAddressAddressLine1
7707 Fannin Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
dei City Area Code
CityAreaCode
832
dei Local Phone Number
LocalPhoneNumber
968-4888
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
KRBP
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1258460
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4379500
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
645200
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1558200
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1043700
CY2023Q3 us-gaap Assets Current
AssetsCurrent
5937700
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1688900
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6581600
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8136900
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1692800
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2117300
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21400
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24400
CY2023Q3 us-gaap Assets
Assets
14233500
CY2022Q4 us-gaap Assets
Assets
11967500
CY2023Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
9600000
CY2022Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
3809900
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4247100
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7308100
CY2023Q3 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1800700
CY2022Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
881600
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
1322800
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
142100
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
57500
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
557200
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
619800
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
584400
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17647900
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13283300
CY2022Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
2914000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1073000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1544900
CY2023Q3 us-gaap Liabilities
Liabilities
18720900
CY2022Q4 us-gaap Liabilities
Liabilities
17742200
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
14000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
15323300
CY2022Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
2
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1176260
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
648384
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1176
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
648
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
113717122
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96172152
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118205700
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101947500
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4487400
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5774700
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14233500
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11967500
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2677200
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3784200
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6718800
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10590700
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2874500
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4611700
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7902800
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13602600
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5551700
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8395900
us-gaap Operating Expenses
OperatingExpenses
14621600
us-gaap Operating Expenses
OperatingExpenses
24193300
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5551700
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8395900
us-gaap Operating Income Loss
OperatingIncomeLoss
-14621600
us-gaap Operating Income Loss
OperatingIncomeLoss
-24193300
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
433800
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1400
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1219300
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
6900
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-3463000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-1730000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-3463000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1792000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1312700
CY2023Q3 krbp Other Income Expense
OtherIncomeExpense
1358200
CY2022Q3 krbp Other Income Expense
OtherIncomeExpense
-3464400
krbp Other Income Expense
OtherIncomeExpense
-1636600
krbp Other Income Expense
OtherIncomeExpense
-3469900
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4193500
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11860300
us-gaap Net Income Loss
NetIncomeLoss
-16258200
us-gaap Net Income Loss
NetIncomeLoss
-27663200
CY2023Q3 krbp Earnings Per Preferred Share Basic
EarningsPerPreferredShareBasic
-254.26
CY2023Q3 krbp Earnings Per Preferred Share Diluted
EarningsPerPreferredShareDiluted
-254.26
krbp Earnings Per Preferred Share Basic
EarningsPerPreferredShareBasic
-1294.31
krbp Earnings Per Preferred Share Diluted
EarningsPerPreferredShareDiluted
-1294.31
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.52
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-22.63
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-22.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-53.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-53.33
CY2023Q3 krbp Weighted Average Number Of Preferred Shares Outstanding Basic
WeightedAverageNumberOfPreferredSharesOutstandingBasic
12891
CY2023Q3 krbp Weighted Average Number Of Preferred Shares Outstanding Diluted
WeightedAverageNumberOfPreferredSharesOutstandingDiluted
12891
krbp Weighted Average Number Of Preferred Shares Outstanding Basic
WeightedAverageNumberOfPreferredSharesOutstandingBasic
7011
krbp Weighted Average Number Of Preferred Shares Outstanding Diluted
WeightedAverageNumberOfPreferredSharesOutstandingDiluted
7011
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1189989
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1189989
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
528015
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
528015
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1040190
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1040190
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
523536
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
523536
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5774700
CY2023Q1 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
85000
CY2023Q1 krbp Adjustments To Additional Paid In Capital Warrant Fair Value
AdjustmentsToAdditionalPaidInCapitalWarrantFairValue
85000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2914000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20700
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5300300
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-8140300
CY2023Q2 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
85900
CY2023Q2 krbp Adjustments To Additional Paid In Capital Warrant Fair Value
AdjustmentsToAdditionalPaidInCapitalWarrantFairValue
85900
CY2023Q2 krbp Stock Issued During Period Preferred Stock New Issues Value
StockIssuedDuringPeriodPreferredStockNewIssuesValue
8000000
CY2023Q2 krbp Stock Issued During Period Commitment Value
StockIssuedDuringPeriodCommitmentValue
659100
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
84600
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35400
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6764400
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6294800
CY2023Q3 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
86900
CY2023Q3 krbp Adjustments To Additional Paid In Capital Warrant Fair Value
AdjustmentsToAdditionalPaidInCapitalWarrantFairValue
86900
CY2023Q3 krbp Stock Issued During Period Preferred Stock New Issues Value
StockIssuedDuringPeriodPreferredStockNewIssuesValue
6000000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
25500
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26400
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4193500
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4487400
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
27319800
CY2022Q1 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
85100
CY2022Q1 krbp Adjustments To Additional Paid In Capital Warrant Fair Value
AdjustmentsToAdditionalPaidInCapitalWarrantFairValue
85100
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
80100
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7367800
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
20032100
CY2022Q2 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
85900
CY2022Q2 krbp Adjustments To Additional Paid In Capital Warrant Fair Value
AdjustmentsToAdditionalPaidInCapitalWarrantFairValue
85900
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
184200
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8435100
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
11781200
CY2022Q3 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
86900
CY2022Q3 krbp Adjustments To Additional Paid In Capital Warrant Fair Value
AdjustmentsToAdditionalPaidInCapitalWarrantFairValue
86900
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
363200
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11860300
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
284100
us-gaap Net Income Loss
NetIncomeLoss
-16258200
us-gaap Net Income Loss
NetIncomeLoss
-27663200
us-gaap Depreciation
Depreciation
1665500
us-gaap Depreciation
Depreciation
1118500
us-gaap Operating Lease Expense
OperatingLeaseExpense
424500
us-gaap Operating Lease Expense
OperatingLeaseExpense
273000
us-gaap Share Based Compensation
ShareBasedCompensation
82500
us-gaap Share Based Compensation
ShareBasedCompensation
627500
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-16200
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
511500
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6100
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2884200
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2928100
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1180700
krbp Increase Decrease In Litigation Liability
IncreaseDecreaseInLitigationLiability
1087500
krbp Increase Decrease In Litigation Liability
IncreaseDecreaseInLitigationLiability
3463000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-168300
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-137000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-436500
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-263400
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15818000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19643400
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
97500
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4823300
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-97500
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4823300
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
19600000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
659100
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
109600
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
499700
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
454500
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19649800
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-454500
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3734300
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24921200
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
645200
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25353900
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4379500
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
432700
us-gaap Interest Paid Net
InterestPaidNet
38600
us-gaap Interest Paid Net
InterestPaidNet
6900
krbp Right Of Use Asset Obtained In Exchange For Operating Lease Liability Asc842 Implementation
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityAsc842Implementation
2232700
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
14000000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2914000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
12800
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1351700
krbp Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
500
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
204800
krbp Deferred Financing Costs Waived
DeferredFinancingCostsWaived
364700
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
30
CY2023Q3 krbp Renegotiated Service Agreement Increase Decrease In Accounts Payable
RenegotiatedServiceAgreementIncreaseDecreaseInAccountsPayable
-1100000
CY2023Q3 krbp Renegotiated Service Agreement Increase Decrease In Accounts Payable
RenegotiatedServiceAgreementIncreaseDecreaseInAccountsPayable
-1100000
CY2023Q3 krbp Renegotiated Service Agreement Increase Decrease In Deferred Finance Costs
RenegotiatedServiceAgreementIncreaseDecreaseInDeferredFinanceCosts
-360000
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
740000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15818000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118205700
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b>—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and public offering common stock, and estimating services incurred by third-party service providers used to recognize research and development expense.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Concentrations of Credit Risk and Other Uncertainties</b>—Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities. </p>
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q3 krbp Dividends Preferred Stock Undeclared
DividendsPreferredStockUndeclared
808200
krbp Dividends Preferred Stock Undeclared
DividendsPreferredStockUndeclared
1323300
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5088600
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
584400
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4193500
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11860300
us-gaap Net Income Loss
NetIncomeLoss
-16258200
us-gaap Net Income Loss
NetIncomeLoss
-27663200
CY2023Q3 krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
25200
CY2022Q3 krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
25200
krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
74700
krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
74800
CY2023Q3 krbp Common Stock Amortization Of Discount
CommonStockAmortizationOfDiscount
61700
CY2022Q3 krbp Common Stock Amortization Of Discount
CommonStockAmortizationOfDiscount
61700
krbp Common Stock Amortization Of Discount
CommonStockAmortizationOfDiscount
183100
krbp Common Stock Amortization Of Discount
CommonStockAmortizationOfDiscount
183100
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5088600
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11947200
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11947200
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17839300
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17839300
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-27921100
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27921100
CY2023Q3 krbp Convertible Debt Instrument Principal Exchanged
ConvertibleDebtInstrumentPrincipalExchanged
14000000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10947400
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10837200
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4365800
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2700300
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6581600
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8136900
CY2023Q3 us-gaap Depreciation
Depreciation
560100
CY2022Q3 us-gaap Depreciation
Depreciation
536600
us-gaap Depreciation
Depreciation
1665500
us-gaap Depreciation
Depreciation
1118500
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
619800
CY2023Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
1087500
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
606600
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
668700
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
106600
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
212900
CY2023Q3 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1800700
CY2022Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
881600
CY2021Q4 krbp Number Of Independent Directors Special Committee
NumberOfIndependentDirectorsSpecialCommittee
3
CY2022Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
2914000
CY2021Q3 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
15385
CY2021Q4 krbp Number Of Lease Amendments
NumberOfLeaseAmendments
2
CY2021Q4 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
3684
CY2022Q2 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
9352
CY2022Q2 krbp Lessee Operating Lease Payments Per Month Years One And Two
LesseeOperatingLeasePaymentsPerMonthYearsOneAndTwo
4800
CY2022Q2 krbp Lessee Operating Lease Payments Per Month Years Three And Four
LesseeOperatingLeasePaymentsPerMonthYearsThreeAndFour
4896
CY2022Q2 krbp Lessee Operating Lease Payments Per Month Year Five
LesseeOperatingLeasePaymentsPerMonthYearFive
5000
CY2022Q2 krbp Operating Lease Lease Cancellation Termination Payment Number Of Months Rent
OperatingLeaseLeaseCancellationTerminationPaymentNumberOfMonthsRent
3
CY2023Q2 krbp Number Of Suites Subleased
NumberOfSuitesSubleased
3
CY2023Q2 krbp Operating Leases Monthly Rent Sublease Rentals
OperatingLeasesMonthlyRentSubleaseRentals
6444
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1692800
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2117300
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1692800
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2117300
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1073000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1544900
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1692800
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2129300
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
179000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
171600
us-gaap Operating Lease Cost
OperatingLeaseCost
537000
us-gaap Operating Lease Cost
OperatingLeaseCost
491600
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M2D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M2D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M2D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M2D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
179400
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
717600
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
724700
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
242800
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1864500
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
171700
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1692800
krbp Short Term Lease Monthly Rental Payments
ShortTermLeaseMonthlyRentalPayments
2500
us-gaap Short Term Lease Cost
ShortTermLeaseCost
22500
krbp Number Of Promissory Notes Outstanding
NumberOfPromissoryNotesOutstanding
4
CY2023Q2 krbp Convertible Debt Instrument Principal Exchanged
ConvertibleDebtInstrumentPrincipalExchanged
8000000
CY2023Q3 krbp Convertible Debt Instrument Principal Exchanged
ConvertibleDebtInstrumentPrincipalExchanged
6000000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
9600000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4000000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
190100
CY2023Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
9600000
CY2022Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
3809900
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1176260
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
648384
CY2023Q3 krbp Number Of Exchange Agreements
NumberOfExchangeAgreements
2
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0001558370-23-019028-index-headers.html Edgar Link pending
0001558370-23-019028-index.html Edgar Link pending
0001558370-23-019028.txt Edgar Link pending
0001558370-23-019028-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
krbp-20230930.xsd Edgar Link pending
krbp-20230930x10q.htm Edgar Link pending
krbp-20230930xex31d1.htm Edgar Link pending
krbp-20230930xex31d2.htm Edgar Link pending
krbp-20230930xex32d1.htm Edgar Link pending
krbp-20230930xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
krbp-20230930x10q_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
krbp-20230930_def.xml Edgar Link unprocessable
krbp-20230930_cal.xml Edgar Link unprocessable
krbp-20230930_lab.xml Edgar Link unprocessable
krbp-20230930_pre.xml Edgar Link unprocessable